Tracking the AVIR option chain helps you see every strike and expiry on Atea Pharmaceuticals Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Atea Pharmaceuticals Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of AVIR options activity at a glance. Use our scanner to monitor the AVIR option chain in real time and filter for the AVIR options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For AVIR stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the AVIR option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where AVIR stock options are being actively traded and where they are not.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection.
It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Atea Pharmaceuticals Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen AVIR options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of AVIR stock options — let the full option chain come to you, pre-filtered and ready to trade.
